1. Indications and Usage
\nGout with Hyperuricemia:
\nIndicated for the treatment of gout with hyperuricemia.
\n2. Dosage and Administration
\nRoute of Administration:
\nOral Use ONLY.
\nRecommended Dosage:
\nInitial Dose: 1 mg administered orally once daily.
\nTitration: The dose should be gradually increased based on serum uric acid levels.
\nMaintenance Dose: Generally 2 mg once daily.
\nMaximum Dose: 4 mg once daily.
\nAdministration Instructions:
\nIncrease fluid intake (at least 2L\/day) to maintain adequate urine volume and alkalize urine to prevent kidney stones.
\n3. Mechanism of Action
\nSelective URAT1 Inhibition:
\nDotinurad is a selective inhibitor of the Urate Transporter 1 (URAT1) in the kidney.
\nPromotion of Excretion:
\nBy inhibiting URAT1, Dotinurad blocks the reabsorption of uric acid in the renal proximal tubules, thereby promoting the excretion of uric acid into the urine and lowering serum uric acid levels.
\n4. Safety and Warnings
\nGout Flare (Acute Attack):
\nContraindication for Initiation: Do not initiate treatment during an acute gout attack. Wait until symptoms subside.
\nManagement: If a gout flare occurs during treatment, continue Dotinurad without dose adjustment and administer anti-inflammatory agents (e.g., NSAIDs, colchicine, corticosteroids) as needed.
\nUrolithiasis (Kidney Stones):
\nIncreased uric acid excretion may lead to kidney stones. Monitor for hematuria or colic. Hydration is mandatory.
\nRenal Impairment:
\nNot recommended for patients with severe renal impairment (eGFR < 30 mL\/min\/1.73 m\u00b2) as efficacy may be reduced.
\nHepatic Impairment:
\nMonitor liver function tests regularly.
\n5. Adverse Reactions
\nMost Common:
\nGouty arthritis (gout flare), gastrointestinal symptoms (diarrhea, soft stools), and elevated liver enzymes.
\n6. Drug Interactions
\nPyrazinamide:
\nMay antagonize the uricosuric effect of Dotinurad; avoid concomitant use.
\nSalicylates (e.g., Aspirin):
\nMay inhibit uric acid excretion and antagonize the effect of Dotinurad.
\n7. Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Dotinurad.
\nAvailable strengths: 1 mg (White to pale yellowish white tablets), 2 mg (Pale red tablets).
\nStorage:
\nStore in a tightly closed container, protected from light and moisture.<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u4f18\u4e50\u601d\u00ae(Urece\u00ae)
\nGeneric Name: Dotinurad
\nStrength: 2mg per tablet, 14 tablets\/blister, 2 blisters\/box (28 tablets total per box)
\nManufacturer: FUJI YAKUHIN CO., LTD. Toyama Plant\uff1bSub-packager: Eisai (China) Pharmaceutical Co., Ltd.
\nMarketing Authorization Holder: FUJI YAKUHIN CO., LTD.
\nApproval Date in China: April 24, 2024
\nRegistration Number: \u56fd\u836f\u51c6\u5b57 HJ20240164
\nStorage: Store sealed below 30\u2103, protect from moisture and direct sunlight; keep out of reach of children.<\/p>\n
Price&Cost:Contact Us now for the best price of Dotinurad\uff08Urece\uff09<\/p>\n","protected":false},"featured_media":3471,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[27],"product_tag":[],"class_list":["post-3470","product","type-product","status-publish","has-post-thumbnail","product_cat-tablets","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n